Form 4: CFO Nelson Sun Buys Aardvark Therapeutics Stock

Aardvark Therapeutics' Chief Financial Officer, Nelson Sun, acquired 3,000 shares of common stock at $14.4 per share in a pre-planned transaction.

Summary

• Nelson Sun, the Chief Financial Officer of Aardvark Therapeutics, Inc., purchased 3,000 shares of the company's common stock.
• The transaction occurred on December 11, 2025, at a price of $14.4 per share.
• Following this acquisition, Mr. Sun beneficially owns a total of 108,484 shares of Aardvark Therapeutics common stock.
• The purchase was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.

Sentiment

Score: 7

Explanation: The Chief Financial Officer's purchase of company stock is generally viewed as a positive signal, indicating management's confidence in the company's future performance and valuation.

Positives

• An insider, specifically the Chief Financial Officer, purchased company stock, which can signal confidence in the company's future prospects and valuation.
• The transaction was executed at a specific price of $14.4 per share, providing a clear valuation point for the insider's investment.

Future Outlook

N/A. This Form 4 filing reports a past insider transaction and does not provide forward-looking statements or guidance.

Industry Context

This insider purchase by the CFO of Aardvark Therapeutics, Inc. is a company-specific event. While insider buying can sometimes reflect management's confidence, it does not directly provide insights into broader industry trends or competitive landscape.

Comparison to Industry Standards

• N/A. This Form 4 filing reports an insider transaction and does not contain information suitable for comparison to industry-wide financial or operational benchmarks.

Corporate Governance

Related Party Transactions

• Nelson Sun, the Chief Financial Officer, purchased 3,000 shares of Aardvark Therapeutics, Inc. common stock, which is a transaction between a company insider and the company's securities.

Stakeholder Impact

• Shareholders: May view the CFO's stock purchase as a positive indicator of management confidence, potentially influencing investor sentiment.

Next Steps

• N/A. This filing reports a completed transaction and does not outline future actions or milestones.

Key Dates

Recommendation

The CFO's purchase of company stock is a positive signal, suggesting confidence in the company's valuation and future prospects. However, a single insider transaction typically warrants a 'hold' recommendation rather than a 'buy' or 'sell' without additional fundamental analysis or broader market context.

Keywords

Aardvark Therapeutics, AARD, Nelson Sun, CFO, Insider Trading, Stock Purchase, Form 4, Equity Acquisition, 10b5-1 plan